Lauren A Millette
Overview
Explore the profile of Lauren A Millette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Domingo C, Busse W, Hanania N, Ertugrul M, Millette L, Maio-Twofoot T, et al.
Allergy
. 2025 Feb;
PMID: 39963805
Asthma is a chronic airway inflammatory disorder, affecting over 350 million people worldwide, with allergic asthma being the most common form of the disease. Allergic asthma is characterized by a...
2.
Chase N, Littlejohn M, Holweg C, Millette L, Seetasith A, Steinke J, et al.
Respir Med
. 2024 Jan;
223:107537.
PMID: 38253245
For patients with moderate-to-severe persistent allergic asthma, omalizumab is approved for subcutaneous administration according to a recommended dosing table based on weight and total immunoglobulin E (IgE) level. The aim...
3.
Meltzer E, Mullol J, Ko J, Saenz R, Steinke J, Millette L, et al.
Int Forum Allergy Rhinol
. 2024 Jan;
14(7):1163-1172.
PMID: 38197558
Background: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) have high incidence of sleep impairment. We evaluated the impact of omalizumab treatment on sleep characteristics and associated health status in...
4.
Casale T, Chipps B, Iqbal A, Yoo B, Millette L, Hanania N
J Allergy Clin Immunol Pract
. 2023 Dec;
12(2):512-514.e2.
PMID: 38070771
No abstract available.
5.
Gevaert P, Mullol J, Saenz R, Ko J, Steinke J, Millette L, et al.
Ann Allergy Asthma Immunol
. 2023 Nov;
132(3):355-362.e1.
PMID: 37951571
Background: Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) often have atopic comorbidities, including elevated IgE levels and comorbid asthma. Omalizumab, an IgE monoclonal antibody, is an effective treatment for...
6.
Witonsky J, Elhawary J, Millette L, Holweg C, Ko J, Raut P, et al.
J Allergy Clin Immunol Pract
. 2023 Apr;
11(9):2911-2913.
PMID: 37088376
No abstract available.
7.
Han J, Yoo B, Saenz R, Braid J, Millette L, Lee S
Int Forum Allergy Rhinol
. 2022 Jan;
12(9):1188-1190.
PMID: 34979056
No abstract available.
8.
Wohlford E, Huang P, Elhawary J, Millette L, Contreras M, Witonsky J, et al.
J Allergy Clin Immunol
. 2021 Sep;
148(5):1324-1331.e12.
PMID: 34536416
Background: Asthma is a heterogeneous disease. Clinical blood parameters differ by race/ethnicity and are used to distinguish asthma subtypes and inform therapies. Differences in subtypes may explain population-specific trends in...
9.
Gevaert P, Wong K, Millette L, Carr T
Clin Rev Allergy Immunol
. 2021 Sep;
62(1):200-215.
PMID: 34536215
Immunoglobulin E (IgE) is a well-known key factor in allergic airway disease; however, its central role in non-allergic airway inflammation is often underestimated. In some airway diseases, IgE is produced...
10.
Damask C, Chen M, Holweg C, Yoo B, Millette L, Franzese C
Am J Rhinol Allergy
. 2021 Aug;
36(1):135-141.
PMID: 34382434
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous disease with variable underlying pathophysiologies. Numerous patient factors have been linked to differences in disease severity, control, and response to...